TORONTO and DALLAS, Sept. 8,
2023 /CNW/ - Perimeter Medical Imaging AI, Inc.
(TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or
the "Company") – a commercial-stage medical technology company –
today announced the appointment of experienced medtech sales
executive, Adam Hodges, as its Vice
President, Sales and Marketing, effective immediately.
Adrian Mendes, Perimeter's Chief
Executive Officer stated, "I am excited to welcome Adam to the
Perimeter team as our senior leader responsible for the strategy
and execution of our sales-related goals. Adam's extensive medtech
background represents a great fit, with his focus on advancing
category-first, novel technologies that challenge the clinical
standard of care and add value to the healthcare system. We believe
our market development managers and other team members in the field
will benefit from his leadership as we expand the number of surgeon
champions and geographical regions adopting our commercially
available S-Series OCT medical imaging platform. Looking ahead, I
expect Adam will also play a key role driving the expansion and
adoption of our next-gen AI-enabled B-Series technology – which is
currently in development – when it reaches a commercial roll-out
stage."
Adam Hodges brings more than 20
years of commercialization experience in the medical device
industry. Most recently, Adam was Vice President of Sales at SIA
Health, leading the commercial acceleration of DuraSorb®, which was
acquired by Integra LifeSciences (NASDAQ: IART) in December 2022. During his tenure at SIA, Adam
grew sales revenue by more than 5X in less than two years and
previously served concurrent roles of Vice President of Strategic
Accounts and Regional Business Director. Prior to that, Adam was VP
of Strategic Accounts for Vapotherm (NYSE: VAPO), driving core
commercial acceleration and identifying and growing adjacent
markets for a novel respiratory therapy technology. From 2009 to
2019, Adam worked at Medtronic in various roles, including Director
of Strategic Accounts, Senior Regional Business Director, and
Account Manager. Earlier in his career, Adam was an Executive
Surgical Device Specialist for United States Surgical
(Covidien/Medtronic) and a Sales Representative for Johnson &
Johnson. Adam began his career in 1998 as a Change Management
Consultant for Accenture. Adam received a Bachelor's degree in
English from Samford University and
then went on to receive a Master of Business Administration
(M.B.A.) in Organizational Leadership from Lipscomb University.
About Perimeter Medical Imaging AI, Inc.
Based
in Toronto, Canada and
Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level. The breakthrough-device-designated investigational Perimeter
B-Series OCT with ImgAssist AI represents our next-generation
artificial intelligence technology that is currently being
evaluated in a pivotal clinical trial, with support from a grant of
up to US$7.4 million awarded by the
Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a
reference to the pink ribbons used during Breast Cancer Awareness
Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains
statements that constitute "forward-looking information" within the
meaning of applicable Canadian securities legislation. In this news
release, words such as "may," "would," "could," "will," "likely,"
"believe," "expect," "anticipate," "intend," "plan," "estimate,"
and similar words and the negative form thereof are used to
identify forward-looking statements. Forward-looking information
may relate to management's future outlook and anticipated events or
results and may include statements or information regarding the
future financial position, business strategy and strategic goals,
competitive conditions, research and development activities,
projected costs and capital expenditures, research and clinical
testing outcomes, taxes and plans and objectives of, or involving,
Perimeter. Without limitation, information regarding the expected
benefits of Mr. Hodges' appointment, the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and ImgAssist AI,
the expected details regarding Perimeter's ongoing clinical trials,
and the benefits from executing upon Perimeter's sales strategies
are forward-looking information. Forward-looking statements should
not be read as guarantees of future performance or results, and
will not necessarily be accurate indications of whether, or the
times at or by which, any particular result will be achieved. No
assurance can be given that any events anticipated by the
forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management's good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter's control. Such forward-looking
statements reflect Perimeter's current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter's
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter's
Management Discussion and Analysis for the year ended December 31, 2022, which is available on
Perimeter's SEDAR+ profile at https://www.sedarplus.ca, and could
cause actual events or results to differ materially from those
projected in any forward-looking statements. Perimeter does not
intend, nor does Perimeter undertake any obligation, to update or
revise any forward-looking information contained in this news
release to reflect subsequent information, events, or circumstances
or otherwise, except if required by applicable laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-strengthens-leadership-team-with-appointment-of-experienced-medtech-executive-adam-hodges-as-vice-president-sales-and-marketing-301921418.html
SOURCE Perimeter Medical Imaging, Inc.
